|
Title
|
|
|
|
Neoadjuvant endocrine treatment in early breast cancer : an overlooked alternative?
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| During the last decade neoadjuvant endocrine therapy (NET) has moved from being reserved for elderly and frail non-chemotherapy candidates to a primary systemic modality in selected patients with hormone sensitive breast cancer. Neoadjuvant hormonal treatment in patients with hormone receptor positive, HER-2 negative early breast cancer is proven to be an effective and safe option; it is associated with a higher rate of breast conserving surgery (BCS), may reduce the need for adjuvant chemotherapy and enables a delay of surgery for medical or practical reasons. Clinical responses range from 13% to 100% with at least 3 months of NET. Methods of assessing response should include MRI of the breast, particularly in lobular tumours. In studies comparing tamoxifen with aromatase inhibitors (AI), AI proved to be superior in terms of tumour response and rates of BCS. Change in Ki67 is accepted as a validated endpoint for comparing endocrine neoadjuvant agents. Levels of Ki67 during treatment are more closely related to long-term prognosis than pretreatment Ki67. Neoadjuvant endocrine therapy provides a unique opportunity for studies of endocrine responsiveness and the development of new experimental drugs combined with systemic hormonal treatment. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
European journal of surgical oncology. - London
|
|
|
Publication
|
|
|
|
London
:
2016
|
|
|
ISSN
|
|
|
|
0748-7983
|
|
|
DOI
|
|
|
|
10.1016/J.EJSO.2015.10.015
|
|
|
Volume/pages
|
|
|
|
42
:3
(2016)
, p. 333-342
|
|
|
ISI
|
|
|
|
000370903000003
|
|
|
Pubmed ID
|
|
|
|
26776766
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|